Drug–Drug Interaction of the Sodium Glucose Co-Transporter 2 Inhibitors with Statins and Myopathy: A Disproportionality Analysis Using Adverse Events Reporting Data

Introduction An increased risk of myopathy due to a potential interaction between sodium glucose co-transporter-2 inhibitors (SGLT-2i) and HMG-CoA reductase inhibitors (statins) has been suggested by case reports. Objective We aimed to assess if the reporting of myopathy is disproportionally higher...

Full description

Saved in:

Bibliographic Details
Published in:	Drug safety Vol. 45; no. 3; pp. 287 - 295
Main Authors:	Alkabbani, Wajd, Pelletier, Ryan, Beazely, Michael A., Labib, Youssef, Quan, Breanna, Gamble, John-Michael
Format:	Journal Article
Language:	English
Published:	Cham Springer International Publishing 01-03-2022 Springer Nature B.V
Subjects:	Atorvastatin Case reports Confidence intervals Datasets Diabetes Diabetes Mellitus, Type 2 - chemically induced Diabetes Mellitus, Type 2 - drug therapy Diabetes Mellitus, Type 2 - epidemiology Drug dosages Drug interaction Drug Interactions Drug Safety and Pharmacovigilance Glucose Glucose transporter Heart failure HMG-CoA reductase inhibitors Humans Hydroxymethylglutaryl-CoA reductase Hydroxymethylglutaryl-CoA Reductase Inhibitors - adverse effects Hypoglycemic Agents Hypotheses Inhibitors Medicine Medicine & Public Health Muscular Diseases - chemically induced Muscular Diseases - epidemiology Myopathy Original Research Article Patients Pharmacokinetics Pharmacology/Toxicology Reductases Rhabdomyolysis Sodium Sodium-Glucose Transporter 2 Inhibitors - adverse effects Statins Symporters United States > US
Online Access:	Get full text
Tags:	Add Tag No Tags, Be the first to tag this record!

Be the first to leave a comment!